ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

8:00AM-9:00AM: Abstract Number: 0571

National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results

Abstracts: Measures and Measurement of Healthcare Quality

8:00AM-9:00AM: Abstract Number: 0574

Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity

Abstracts: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science

8:00AM-9:00AM: Abstract Number: 0566

SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children

Abstracts: Pediatric Rheumatology – Basic Science

8:00AM-9:00AM: Abstract Number: 0573

Telehealth versus Outpatients Clinic Follow up in Rheumatoid Arthritis Patients a Randomized Controlled Study

Abstracts: Measures and Measurement of Healthcare Quality

8:00AM-9:00AM: Abstract Number: 0568

The Absence of Blk Leads to Increased Inflammation in a Murine Model of Kawasaki Disease

Abstracts: Pediatric Rheumatology – Basic Science

9:00AM-10:30AM: Abstract Number: 0580

18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis

Cytokines and Cell Trafficking Poster

9:00AM-10:30AM: Abstract Number: 0812

3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0856

A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 1051

A Deep Neural Network Classifier to Identify Intrinsic Molecular Subsets of Systemic Sclerosis Using Histological Images

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0593

A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 1047

A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0752

A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0628

A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0987

A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0998

A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US

SLE – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].